Multibagger pharma penny stock under Rs 20 hit upper circuit after receiving an order worth Rs 11.59 crore from Rajasthan Medical Services Corporation Ltd
The stock gave multibagger return of 2,500 per cent in 3 years and a whopping 8,450 per cent in 5 years.
On Friday, shares of Shukra Pharmaceuticals Ltd were locked in a 2 per cent upper circuit to Rs 13.66 per share from its previous closing of Rs 13.40 per share. The stock’s 52-week high is Rs 27.15 while its 52-week low is Rs 5.75 per share.
Shukra Pharmaceuticals Limited has received a Letter of Acceptance dated June 24, 2025, from Rajasthan Medical Services Corporation Limited (RMSCL), confirming a Rate Contract cum Supply Agreement for the provision of essential pharmaceutical formulations to government health institutions throughout Rajasthan. This significant domestic contract, valued at Rs. 11.59 Crore, is scheduled for completion by December 2026. The company views this prestigious award as a major step that will enhance its visibility in the institutional segment, significantly contribute to its revenue, and align with its strategic goal of expanding its presence in government procurement channels.
Additionally, the Board of Directors of Shukra Pharmaceuticals Ltd recommended a Final dividend of Re 0.01 (1 per cent) per equity share of Re 1 each. This dividend, which is subject to tax deductions, will be paid for the financial year 2024-25, pending approval from shareholders at the company's upcoming Annual General Meeting.
DSIJ’s ‘Micro Marvel' service recommends micro-cap stocks with the potential to grow multifold in long run. If this interests you, do download the service details here.
Established in 1993, Shukra Pharmaceuticals Ltd. operates in both manufacturing and trading pharmaceuticals, alongside offering laboratory testing services. The company has a market cap of over Rs 598.14 crore with a 3-year stock price CAGR of 190 per cent.
The company reported positive results in both quarterly and annual financial statements. In Q4FY25, the company reported net sales of Rs 13.27 crore and net profit of Rs 5.39 crore. In FY25, the company did net sales of Rs 32.59 crore and net profit of Rs 9.58 per share.
According to the shareholding, the promoters own a 50.95 per cent stake in the company while DIIs own 0.11 per cent and the public owns 48.94 per cent as of March 2025. The stock gave multibagger return of 2,500 per cent in 3 years and a whopping 8,450 per cent in 5 years.
Disclaimer: The article is for informational purposes only and not investment advice.